The full data in the New England Journal of Medicine was generally consistent with prior data cuts and the clinical profile of Aimmune Therapeutics' AR101 remains compelling, Piper Jaffray analyst Christopher Raymond tells investors in a research note. While some investors may point to an imbalance in epinephrine use as marring the drug's profile, this should not come as a surprise, adds the analyst. He views the drug's "clear benefit" on tolerated dose upon exit food challenge as the more important measure. Raymond thinks the stock's set-up "remains decidedly positive" with potential approval in mid-2019 and revenue potential exceeding $1B. The analyst keeps an Overweight rating on Aimmune with a $60 price target.